Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00050661
Status:
COMPLETED
Last Update Posted:
2009-03-25
First Post:
2002-12-17
Brief Title:
To Study the Use of Humanized CD25 in Preventing the Relapse of Psoriasis Vulgaris
Sponsor:
Rockefeller University
Organization:
Rockefeller University
Study Overview
Official Title:
Use of Humanized CD25 Anti-TAC Monoclonal Antibody Placebo to Prevent Relapse of Psoriasis Vulgaris Following NBUVB Therapy
Status:
COMPLETED
Status Verified Date:
2009-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study is designed to study disease relapse after NBUVB and how the administration of Daclizumabplacebo alters disease relapse
Detailed Description:
The first part of the study involves NB-UVB light treatment a well-established treatment to treat psoriasis In the second part we are testing a drug known as Humanized CD25 Monoclonal Antibody anti-TAC or placebo to prevent disease relapse Anti-TAC is an injectable medicine that is also designed to treat psoriasis by blocking a part of the immune system that we believe contributes to the disease
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None